Back to top
more

Aprea Therapeutics (APRE)

(Delayed Data from NSDQ)

$1.64 USD

1.64
68,082

-0.15 (-8.38%)

Updated Aug 6, 2025 03:59 PM ET

After-Market: $1.64 0.00 (0.00%) 4:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -3.49% and 34.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Merus (MRUS) delivered earnings and revenue surprises of 56.84% and 22.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Aprea Therapeutics (APRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aprea Therapeutics (APRE) delivered earnings and revenue surprises of 14.67% and 21.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

XOMA Royalty (XOMA) delivered earnings and revenue surprises of 11.36% and 8.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacira (PCRX) Q3 Earnings Beat Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 9.72% and 0.91%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aprea Therapeutics (APRE) delivered earnings and revenue surprises of 9.38% and 462%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -5.71% and 53.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze

by Zacks Equity Research

The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.

Zacks Equity Research

FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma

by Zacks Equity Research

The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.

Zacks Equity Research

Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Aprea Therapeutics, Inc. (APRE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy

by Zacks Equity Research

Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies

by Zacks Equity Research

Aprea Therapeutics (APRE) advances its novel macrocyclic ATR inhibitor into early-stage clinical studies for treating advanced solid tumors.

Zacks Equity Research

Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Biotech Stock Roundup: BMY Increases Dividend, MRNA's Study Results & More

by Zacks Equity Research

Moderna's (MRNA) vaccine study results and other pipeline updates have been the biotech sector???s few key highlights during the past week.

Zacks Equity Research

Aprea (APRE) Reports FDA Removal of Clinical Hold on Study

by Zacks Equity Research

The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.

Zacks Equity Research

Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?

by Zacks Equity Research

Investors need to pay close attention to Aprea Therapeutics (APRE) stock based on the movements in the options market lately.

Zacks Equity Research

Implied Volatility Surging for Aprea (APRE) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.

Zacks Equity Research

Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

by Zacks Equity Research

Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.

Zacks Equity Research

All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy

by Zacks Equity Research

Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

What Makes Aprea Therapeutics, Inc. (APRE) a New Buy Stock

by Zacks Equity Research

Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More

by Zacks Equity Research

The biotech sector was in focus last week with COVID-19 vaccine study update from Novavax (NVAX) and antibody cocktail treatment update from Regeneron (REGN).

Zacks Equity Research

Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal

by Zacks Equity Research

Aprea (APRE) down as late-stage study on lead candidate, eprenetapopt, combined with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS) fails.

Zacks Equity Research

How Aprea Therapeutics (APRE) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Aprea Therapeutics (APRE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Aprea Therapeutics (APRE) in Focus: Stock Moves 5.8% Higher

by Zacks Equity Research

Aprea Therapeutics (APRE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.